Lysophosphatidic acid receptor 1 (LPA₁) plays critical roles in microglial activation and brain damage after transient focal cerebral ischemia.

ABSTRACT:

Background

Lysophosphatidic acid receptor 1 (LPA₁) is in the spotlight because its synthetic antagonist has been under clinical trials for lung fibrosis and psoriasis. Targeting LPA₁ might also be a therapeutic strategy for cerebral ischemia because LPA₁ triggers microglial activation, a core pathogenesis in cerebral ischemia. Here, we addressed this possibility using a mouse model of transient middle cerebral artery occlusion (tMCAO).

Methods

To address the role of LPA₁ in the ischemic brain damage, we used AM095, a selective LPA₁ antagonist, as a pharmacological tool and lentivirus bearing a specific LPA₁ shRNA as a genetic tool. Brain injury after tMCAO challenge was accessed by determining brain infarction

SUBMITTER: Gaire BP 

PROVIDER: S-EPMC6701099 | biostudies-literature | 2019 Aug

REPOSITORIES: biostudies-literature